Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring minimal residual disease in the bone marrow using next generation sequencing.

Best practice & research. Clinical haematology - 1 Mar 2020

Rustad Even H, Boyle Eileen M

Abstract excerpt

Achieving minimal residual disease (MRD) negativity in the bone marrow is one of the strongest prognostic factors in multiple myeloma. Consequently, MRD testing is routinely performed in clinical trials and moving towards standard of care. This review focuses on the role of next generation sequencing (NGS) of tumor-specific immunoglobulin V(D)J sequences for MRD tracking. The immunoglobulin variable regions are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Cell Count
Share to Immunoglobulin Variable Region

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Multiple Myeloma

Share to Neoplasm, Residual

Share to Plasma Cells

Share to Recurrence

Share to V(D)J Recombination

Source

Open in PubMed Open full text

Identifiers

PMID: 32139014
DOI: 10.1016/j.beha.2020.101149
PMCID: PMC7133460

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring minimal residual disease in the bone marrow using next generation sequencing.PMID 32139014Read ↗

Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic useSemantic proximity Read ↗

Cell-free DNA Whole Genome Sequencing for Non-Invasive Minimal Residual Disease Detection in Multiple MyelomaSemantic proximity Read ↗

Molecular detection of minimal residual disease in multiple myelomaSemantic proximity Read ↗

Utilizing next-generation sequencing in the management of multiple myeloma.Semantic proximity Read ↗

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myelomaSemantic proximity Read ↗

Minimal Residual Disease Monitoring with Next-Generation Sequencing Methodologies in Hematological MalignanciesSemantic proximity Read ↗

Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedsideSemantic proximity Read ↗

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myelomaSemantic proximity Read ↗

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future PerspectivesSemantic proximity Read ↗

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment.Semantic proximity Read ↗

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myelomaSemantic proximity Read ↗

Circulating Tumour DNA for Detecting Minimal Residual Disease in Multiple MyelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.